Taken together, our findings define a novel strategy to promote anti-tumor immunity in colitis-associated colorectal carcinogenesis, specifically by targeting SHP2 to trigger IFN-γ signaling and the subsequent CTL activity. This evidence concerns the gene PTPN11 and colitis.